The Biden administration released the list of 27 Medicare Part B drugs that are subject to rebates back to the government for having price increases that rose faster than inflation as well as the removal of out-of-pocket costs for some vaccines covered under Part D.
The Biden administration Wednesday released the list of 27 Medicare Part B drugs that are subject to rebates back to the government as allowed under the Inflation Reduction Act (IRA) for having price increases that rose faster than inflation.
In addition, the administration touted a part of the law that removed cost sharing for vaccines for Medicare beneficiaries, saying that if the policy had been in place in 2021, 3.4 million individuals receiving vaccines under Part D would have saved $70 per beneficiary.
The list of Part B drugs includes the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel, sold as Yescarta; the CAR T-cell therapy brexucabtagene autoleucel, sold as Tecartus; the brand-name biologic adalimumab, sold as Humira; and the ophthalmologic drug triamcinolone acetonide injectable suspension, sold as Xipere.
Rebates for 2023 and 2024, which will go back into the Medicare Trust Fund, will not be invoiced to pharma manufacturers until 2025.
Beneficiaries in traditional fee-for-service Medicare as well as Medicare Advantage may see a difference in what they pay as soon as next month, depending on the dose of the Part B drug as well as how often it is administered, HHS and CMS officials said Tuesday. They estimated that the out-of-pocket cost reduction could range from $2 to as high as $390 per average dose.
The administrating is hoping that by being compelled to send rebates back to the government, drug companies will be incentivized to keep any price increases below the level of inflation. Companies failing to pay the rebate will face a penalty equaling 125% of the rebate amount.
President Joe Biden is scheduled to talk about drug pricing in a speech Wednesday in Las Vegas.
In its report about vaccines, HHS said that about 51 million Medicare beneficiaries are enrolled in a Part D plan. Looking at vaccine coverage under Part D, including ones to prevent herpes zoster (shingles); tetanus and diphtheria (Td); tetanus, diphtheria, and pertussis (Tdap); hepatitis A; and hepatitis B, HHS said only 7% of enrollees received a covered vaccine. Total OOP costs were $234 million in 2021.
Most of the beneficiaries received the shingles vaccine (82%), with each patient paying an average of $77 in OOP costs, followed by the Tdap vaccine (21%), with an average of $28 in OOP costs.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More